Key result
Cardiac-specific Trim44 knockout in rats attenuated isoproterenol-induced pathological cardiac remodeling and dysfunction by inhibiting the AKT/mTOR/GSK3β/P70S6K signaling pathway.
Why the study?
When pathological hypertrophy progresses to HF, the prognosis is often very poor, making it crucial to find new and effective intervention targets.
Trim44 knockout protects against isoproterenol-induced pathological cardiac remodeling by inhibiting the AKT/mTOR signaling pathway, suggesting Trim44 as a potential therapeutic target for cardiac hypertrophy and heart failure.
Answers are grounded in this paper and cite their sources.
Trim44 inhibition attenuates remodeling in rats; leaves open translation to human heart failure therapies.
When pathological hypertrophy progresses to heart failure (HF), the prognosis is often very poor. Therefore, it is crucial to find new and effective intervention targets. Here, myocardium-specific Trim44 knockout rats were generated using CRISPR-Cas9 technology. Cardiac phenotypic observations revealed that Trim44 knockout affected cardiac morphology at baseline. Rats with Trim44 deficiency exhibited resistance to cardiac pathological changes in response to stimulation via isoproterenol (ISO) treatment, including improvement of cardiac remodeling and dysfunction by morphological and functional observations, reduced myocardial fibrosis and reduced expression of molecular markers of cardiac stress. Furthermore, signal transduction validation associated with growth and hypertrophy development in vivo and in vitro demonstrated that Trim44 deficiency inhibited the activation of signaling pathways involved in myocardial hypertrophy, especially response to pathological stress. In conclusion, the present study indicates that Trim44 knockout attenuates ISO-induced pathological cardiac remodeling through blocking the AKT/mTOR/GSK3β/P70S6K signaling pathway. This is the first study to demonstrate the function and importance of Trim44 in the heart at baseline and under pathological stress. Trim44 could be a novel therapeutic target for prevention of cardiac hypertrophy and HF.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2022) studied Cardiac hypertrophy and remodeling. Cardiac-specific Trim44 knockout vs. Wild-type control was evaluated on Cardiac remodeling and dysfunction (echocardiographic and histological parameters). Cardiac-specific Trim44 knockout in rats attenuated isoproterenol-induced pathological cardiac remodeling and dysfunction by inhibiting the AKT/mTOR/GSK3β/P70S6K signaling pathway.
Synapse has enriched 10 related papers. Consider them for comparative context: